*.- Una de cada nueve mujeres padecerá en algún momento de su vida la enfermedad .
*.- Los avances permiten un nivel de curación del 80% y una mejor calidad de vida .
Natalia Ortiz /// 4-12-2014 .
Adoptar unos hábitos saludables y llevar una dieta equilibrada reducen hasta un 50 por ciento la posibilidad de padecer cáncer de mama, el tipo de tumor más frecuente entre las mujeres y que, en algún momento de su vida, sufrirá una de cada nueve españolas.
Ésta es una de las principales conclusiones extraídas del Observatorio sobre el Cáncer de Mama organizado por EL MUNDO de Andalucía, en el que se repasaron los principales avances en el diagnóstico y las terapias y se dieron a conocer dos realidades sustanciales en el abordaje de la patología: por un lado, cada vez son más las mujeres que padecen cáncer de mama; y, por otro, la posibilidad de sobrevivir en buenas condiciones de vida a la enfermedad es también significamente mayor.
...
04 diciembre 2014
PM01183 . La lucha contra el cáncer cotiza al alza: Zeltia anuncia el éxito de otro medicamento .
Zeltia vuelve a ser protagonista esta semana. Si el lunes anunciaba la fusión con su filial Pharmamar con la intención de dar el salto a los mercados de Estados Unidos, hoy son los buenos resultados obtenidos en sus investigaciones contra el cáncer de ovario los que cotizan al alza en bolsa. Sus acciones suben en bolsa más de un 2,5% hasta los 2,8 euros.
La compañía ha comunicado que su medicamento PM1183, en fase IIb de estudio para tratar pacientes con cáncer de ovario platino-resistente han logrado una media de supervivencia de 18,1 meses frente a los 8,5 meses de los tratados con topotecán.
De esta manera, los buenos resultados han provocado el paso de la investigación a Fase III, que es el previo a la solicitud de registro del medicamento para el tratamiento de este tipo de tumores.
Así, la historia de Zeltia en bolsa vuelve a ser la de sus comunicados. Sin ir más lejos, la semana pasada la compañía que preside José María Fernández de Sousa se volvía a disparar un 6,5% tras anunciar que Pharmamar, a través de su socio Janssen Reserach & Development, había presentado ante la agencia del medicamento de EEUU (FDA por sus siglas en ingles) una solicitud de registro de Yondelis para el tratamiento del sarcoma de tejidos blandos avanzado.
PM01183 consigue una Media de Supervivencia Global en el Tratamiento de Cáncer de Ovario Platino Resistente ... de 18,1 Meses Frente a los 8,5 Meses que Consigue Topotecan ... el Farmaco de Referencia .
Pharma Jonpi : Con un Farmaco asi ... si se puede salir a cotizar en EEUU .
12/04/2014 /// ZELTIA NEWS .
PharmaMar reports Phase IIb results for PM1183 showing a median overall survival of 18.1 months compared to 8.5 months for topotecan in platinum-resistant ovarian cancer patients
PharmaMar will start a pivotal phase 3 trial with platinum-resistant patients to assess efficacy of PM1183 in a larger population in the first half of 2015
The data show that PM1183 is superior compared to topotecan regarding median overall survival
Madrid, December 4, 2014: Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan. In this multicenter Phase IIb randomized trial, platinum- resistant ovarian patients treated with PM1183 lived longer, with a median overall survival of 18.1 months, compared to topotecan, which only achieves 8.5 months. PharmaMar will launch a pivotal Phase III trial to confirm the efficacy of PM1183 in a larger population, and that is expected to be the final step before registration of PM1183 for platinum-resistant ovarian cancer.
"The pivotal trial planned for next year will hopefully confirm the effects in survival that we observe in these patients, who are in need of drugs that will reduce the risk of death and extend their lives, without posing major side effects", says Arturo Soto, Director of Clinical Development, PharmaMar.
The Phase IIb trial consisted of a first stage, single arm approach to assess efficacy of
PM1183 in platinum-resistant ovarian cancer patients, followed by a second stage, in which patients were randomized to be treated with PM01183 or topotecan as control group.
Results presented at the American Society of Clinical Oncology (ASCO) earlier this year showed a significant improvement in the other secondary endpoint, progression-free survival, as well as in the overall response rate, which was the primary endpoint1. The results found now for the overall survival of patients with platinum-resistant ovarian cancer treated with PM1183 add to the clinical benefit, measured as 70% of overall responses and stable disease, previously observed. The manageable safety profile previously described for these patients has not changed.
12/04/2014 /// ZELTIA NEWS .
PharmaMar reports Phase IIb results for PM1183 showing a median overall survival of 18.1 months compared to 8.5 months for topotecan in platinum-resistant ovarian cancer patients
PharmaMar will start a pivotal phase 3 trial with platinum-resistant patients to assess efficacy of PM1183 in a larger population in the first half of 2015
The data show that PM1183 is superior compared to topotecan regarding median overall survival
Madrid, December 4, 2014: Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan. In this multicenter Phase IIb randomized trial, platinum- resistant ovarian patients treated with PM1183 lived longer, with a median overall survival of 18.1 months, compared to topotecan, which only achieves 8.5 months. PharmaMar will launch a pivotal Phase III trial to confirm the efficacy of PM1183 in a larger population, and that is expected to be the final step before registration of PM1183 for platinum-resistant ovarian cancer.
"The pivotal trial planned for next year will hopefully confirm the effects in survival that we observe in these patients, who are in need of drugs that will reduce the risk of death and extend their lives, without posing major side effects", says Arturo Soto, Director of Clinical Development, PharmaMar.
The Phase IIb trial consisted of a first stage, single arm approach to assess efficacy of
PM1183 in platinum-resistant ovarian cancer patients, followed by a second stage, in which patients were randomized to be treated with PM01183 or topotecan as control group.
Results presented at the American Society of Clinical Oncology (ASCO) earlier this year showed a significant improvement in the other secondary endpoint, progression-free survival, as well as in the overall response rate, which was the primary endpoint1. The results found now for the overall survival of patients with platinum-resistant ovarian cancer treated with PM1183 add to the clinical benefit, measured as 70% of overall responses and stable disease, previously observed. The manageable safety profile previously described for these patients has not changed.
Suscribirse a:
Entradas (Atom)